PATRICK WILLIAMS, M.D.
Ophthalmology Physician · ARLINGTON, TX
Individual Active NPI 1154306777
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 980 | 43,227 | $10,997,421 | $3,930,745 | $3,095,695 |
| 2023 | 959 | 35,211 | $10,188,268 | $3,662,068 | $2,880,421 |
| 2022 | 1,017 | 14,304 | $9,731,088 | $3,516,977 | $2,762,051 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | 29,762 | $35 | $28 |
| 92134 | Imaging of retina | 2,615 | $42 | $32 |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 1,770 | $147 | $117 |
| J0178 | Injection, aflibercept, 1 mg | 1,579 | $826 | $657 |
| J2782 | Injection, avacincaptad pegol, 0.1 mg | 1,550 | $109 | $86 |
| 67028 | Injection of drug into eye | 1,503 | $129 | $97 |
| 92014 | Established patient complete exam of visual system | 1,220 | $130 | $91 |
| J0177 | Injection, aflibercept hd, 1 mg | 1,057 | $331 | $264 |
| 92012 | Established patient problem focused exam of visual system | 773 | $92 | $68 |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 210 | $202 | $161 |
| 99204 | New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more | 119 | $172 | $129 |
| 92004 | New patient complete exam of visual system | 107 | $155 | $116 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Ophthalmology Physician | 207W00000X | ✓ | M1405 | TX |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Ophthalmology Physician providers in Texas
- NPI 1629188073
- NPI 1649521873
- NPI 1164426946
- NPI 1174712483
- NPI 1922002302
- NPI 1851324909
- NPI 1093707721
- NPI 1366744583
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.